糖皮质激素受体与新型糖皮质激素受体调节剂的研究进展  

Research Progress of Glucocorticoid Receptor and New Glucocorticoid Receptor Modulators

作　　者：王丁丁 戈晓爱 成丽媛 张雨建 王涛[1] WANG Dingding;GE Xiaoai;CHENG Liyuan;ZHANG Yujian;WANG Tao(New Drug Screening Center,Jiangsu Center for Pharmacodynamic Research and Evaluation,China Pharmaceutical University,Nanjing 210009,China)

机构地区：[1]中国药科大学新药筛选中心、江苏省药效研究与评价服务中心,江苏南京210009

出　　处：《药学进展》2023年第5期392-400,I0003-I0006,共13页Progress in Pharmaceutical Sciences

摘　　要：外源性糖皮质激素(GCs)在临床上广泛用于治疗炎症性疾病,其机制主要通过糖皮质激素受体(GR)发挥作用。但长期大量的使用GCs引起的不良反应使得GCs的使用受到限制,学术界正不断努力寻找更安全的GR调节剂。通过对GR的作用机制及长期使用GCs导致的不良反应进行介绍,同时,总结了近年来更安全的新型GR调节剂的研究进展,以期为新型GR配体的研发提供参考。Exogenous glucocorticoids(GCs)are widely used in clinical treatment of inflammatory diseases,with their mechanism of action mainly through glucocorticoid receptor(GR).However,the use of GCs is limited by the adverse reactions caused by their longterm and large-scale application.The academic community is making continuous efforts to find safer GR regulators.This article introduces the mechanism of GR and the adverse reactions caused by long-term use of GCs,and summarizes the research progress of new safer GR modulators in recent years,in order to provide some reference for the development of new GR ligands.

关 键 词：糖皮质激素受体 糖皮质激素受体调节剂 二聚体 不良反应 

分 类 号：R977.1[医药卫生—药品]